31.   However, generic competitors including Genpharm will still have to resolve legal differences with Glaxo before marketing the drug, she said.

32.   If approved, the company would market the drug for smoking cessation as Bupropion to distinguish it from the anti-depressant form of the drug.

33.   If approved, GlaxoSmithKline will market the drug in the United States and Europe.

34.   If approved, the drug would be marketed by Madison, New Jersey based Schering-Plough.

35.   In September, she flew to Washington to testify before an FDA advisory committee considering whether Celgene should be permitted to market the drug.

36.   InfiMed plans to market the drug itself in the US market, and it has partnered with Novartis in Europe.

37.   Instead, it has been teaming up with other manufacturers to develop and market some drugs jointly.

38.   It also plans to market the drug with its own sales force.

39.   It could also determine the future of the already strained partnership between Bristol-Myers and ImClone to develop and market the drug.

40.   It will also include another recent acquisition, New Jersey-based Carnrick Laboratories, which markets drugs for headaches, arthritis and allergic conditions.